Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Otorhinolaryngology

Show all topics

DOI

10.1016/s0140-6736(19)32591-7

Other Formats

PDF